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1 OUT OF EVERY 4 WOMEN 
in low- and middle-income countries 
want to delay or prevent pregnancy  
but are not using a modern  
contraceptive method. 
SOURCES: 
Singh, S., J.E. Darroch, and L.S. Ashford. 2014. Adding It Up: The Costs and Benefits of Investing in Sexual and  
Reproductive Health 2014. New York: Guttmacher Institute. 
UNAIDS. 2014. The Gap Report. Geneva: UNAIDS. 
World Health Organization. 2013. “Sexually transmitted infections (STIs).” Fact sheet. Geneva: WHO. 1
EVERY DAY MORE THAN
 1 MILLION PEOPLE 
contract sexually transmitted  
infections (STIs)  
that can cause:
CONSIDER THESE NUMBERS:
EVERY DAY NEARLY  
6,300 PEOPLE
become infected with  
HIV, disproportionately  
affecting young women aged 
15-24 in pandemic regions.
CANCER
INFERTILITY
PREGNANCY 
COMPLICATIONS
INCREASED 
HIV RISK
 
225 
MILLION
New prevention options 
aimed at reducing 
unintended pregnancy 
and the transmission of 
HIV and other STIs are 
urgently needed.
The Population Council 
is meeting this challenge 
by developing new 
technologies and products 
to help people enhance 
their health and wellbeing.
by Julia Bunting
RESEARCH AND 
DEvELOPmENT 
TO IMPROVE 
REPRODUCTIVE 
HEALTH
Since it was founded in 1956, the 
Population Council’s Center for 
Biomedical Research (CBR) has 
specialized in researching and 
developing drugs, technologies, 
and products that enable women, 
men, and young people to protect 
and enhance their reproductive 
health and wellbeing. Hundreds of 
millions of women have used a family 
planning method developed by the 
Council, including the Copper T IUD, 
the Mirena® intrauterine system, the 
implants Norplant® and Jadelle®,  
and the progesterone contraceptive 
vaginal ring for breastfeeding women. 
Since the beginning of the HIv 
epidemic in the 1980s, the Council 
has also conducted research to identify 
new, user-controlled methods to 
prevent HIv infection.
Today, Council scientists at CBR are 
researching new technologies—rings, 
gels, and other systems—to provide 
even greater contraceptive choice 
as well as protection from HIv and 
other sexually transmitted infections. 
my colleagues identify leads for new 
products, develop the most promising 
ideas through years of research, work 
with regulatory authorities to secure 
approval for these technologies, and 
collaborate with pharmaceutical 
companies, governments, and a 
host of other partners to bring these 
products to market. This work is 
literally improving the lives of millions 
PRESIDENT’S mESSAGE
of people around the world today and 
the benefits of these investments will 
continue for generations to come. 
In this issue of momentum you will  
read about the Council’s rich and 
distinguished history of biomedical 
research and the significant impact 
of this work on women’s reproductive 
health (page 4). You will see how the 
Council continues to be at the cutting 
edge of developing new contraceptive 
vaginal rings (page 10), as well as the 
Council’s work to expand access to 
long-acting reversible contraception 
(page 12). Council researchers are 
also exploring innovative contracep-
tive methods for men (page 6), and 
multipurpose prevention technologies 
to protect against various sexual and 
reproductive health risks (page 8).  
You will meet Council scientist José 
Fernández Romero, who is identifying 
new ways to prevent HIv and other sex-
ually transmitted infections (page 14), 
and Barbara Ebert, a decades-long sup-
porter of the Council’s work to develop 
new contraceptive methods (page 15).
I am deeply honored to have joined 
the Population Council, and I am 
committed to building on our strong 
legacy and investing in a bright future 
of biomedical research. 
Together we will continue  
to provide women, men,  
and young people around the 
world with new products to 
safeguard their wellbeing and 
help them live more productive, 
healthier lives.  
Thank you for your support.
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nal ring (Progering®) that can be used 
by breastfeeding women.
In parallel Council scientists have con-
ducted biomedical research on the 
sexual transmission of HIv and worked 
toward development of new prevention 
technologies ever since HIv infection 
and AIDS were recognized as emerging 
public health crises in the 1980s. The 
Council’s Carraguard® gel was the first 
product developed as a microbicide to 
complete a Phase III efficacy trial—a 
milestone in HIv prevention research. 
Although Carraguard was not found to 
be effective for HIv prevention, R&D for 
microbicides and multipurpose preven-
tion technologies (MPTs) continues to 
evolve. The Council is now advancing 
promising options for user-controlled 
prevention of HIv and other STIs, as well 
as MPTs that provide contraception in 
addition to HIv and/or STI prevention.
Today CBR is a vibrant hub of R&D on 
the campus of Rockefeller University 
in New York City—and the need for new 
sexual and reproductive health tech-
nologies is just as urgent now as it was 
nearly 60 years ago. The R&D process 
is long and complex, particularly when 
products are being developed for low-
resource settings where diverse needs 
and challenges must be addressed. 
Council discoveries have led to identi-
fying potential added health benefits 
of several products in the pipeline, 
such as protective effects of novel 
contraceptive hormones on breast 
and prostate health. Basic science re-
search at CBR has also opened doors 
to exploring new treatments for chronic 
conditions such as uterine fibroids and 
multiple sclerosis.
The Council proudly invests in the 
full R&D lifecycle, taking a “bench to 
bedroom” approach that focuses on 
end-users from the start and works 
with partners to identify and fill product 
niches that are otherwise not profitable 
for traditional biotechnology or pharma-
ceutical companies. The Council’s R&D 
efforts lead to safe and effective prod-
ucts that are acceptable, accessible, 
and designed to meet people’s varying 
sexual and reproductive health needs 
at different points in their lives.
The Population Council’s Center for 
Biomedical Research (CBR) is at the 
vanguard of global research and develop-
ment (R&D) efforts focusing on contra-
ception, preventing HIV and other sexually 
transmitted infections (STIs), and identify-
ing novel approaches to improve health.
The Council helped establish the field 
of long-acting, reversible contraception 
(LARC) in the early 1960s, working with 
international partners to develop the “T” 
shape of the modern intrauterine device 
(IUD) and identifying the contraceptive ac-
tion of copper. The Council’s first Copper 
T IUD was approved by the US Food and 
Drug Administration in 1976; in 1984, 
the FDA approved the Council’s 10-year 
Copper T380 IUD (ParaGard®)—the 
most popular nonsurgical contraceptive 
method used worldwide. 
Contraceptive implant technology was 
another breakthrough spearheaded 
by the Council in the mid-1960s, cul-
minating in the five-year hormonal 
implant systems known as Norplant® 
and Jadelle® (approved by the FDA in 
1990 and 1996, respectively). Other 
LARC methods pioneered by Council 
researchers and partners include the 
five-year Mirena® intrauterine system 
and a three-month progesterone vagi-
In 1956 the Population 
Council established one  
of the first laboratories  
dedicated to the research  
and development of new 
technologies to protect 
reproductive health.
 FROm BENCH TO BEDROOm: 
BIOMEDICAL 
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76
synthetic progestin reduces sperm count 
more quickly and effectively.
THE IMPACT  New, effective options 
for male contraception would expand the 
mix of available family planning methods. 
Among men who reported being inter-
ested in using male contraception, 30% 
said they would prefer implants. Unlike 
testosterone, mENT does not enlarge the 
prostate; and because of its high potency, 
a low daily dose can be administered, 
making delivery through an implant sys-
tem preferable for long-term use. Discov-
ery of the second active component will 
take the mENT implant technology one 
step closer to becoming a viable LARC 
option for men.
PARTNERS  Bayer Schering HealthCare; 
Christina Wang (David Geffen School of 
medicine, University of California, Los 
Angeles); Crystal Pharma; David T. Baird 
(U.K. medical Research Council [mRC] Centre 
for Reproductive Health at the University of 
Edinburgh [formerly the mRC Reproductive 
Biology Unit]); Eberhard Nieschlag (Center 
for Reproductive medicine and Andrology of 
the University Hospital of munster, Germany); 
Horacio Croxatto (Instituto Chileno de 
medicina Reproductiva [ICmER], Santiago, 
Chile); Richard Anderson (U.K. mRC Centre 
for Reproductive Health at the University of 
Edinburgh) 
DONORS  U.S. National Institutes of Health 
Eunice Kennedy Shriver National Institute of 
Child Health and Human Development; The 
George J. Hecht Fund; The Lita Annenberg 
Hazen Foundation; The William and Flora 
Hewlett Foundation; Population Council
THE PROBLEM  There is a recog-
nized need for long-acting reversible 
contraception (LARC) for men, but as yet 
there are no available methods. Stud-
ies suggest that women and men would 
enthusiastically welcome additional male 
contraceptive choices, which would en-
able men to better share the responsibil-
ity, risks, and costs of family planning. 
The male reproductive system offers 
several potential targets for both hor-
monal and non-hormonal contraception; 
however, many challenges exist including 
the necessity of stopping daily produc-
tion of millions of sperm. A safe, effec-
tive, acceptable male LARC requires an 
approach that will reduce sperm count 
without daily use.
THE PROGRESS  Through the devel-
opment of MENT® from a synthetic steroid 
that resembles testosterone, research-
ers have discovered that administering 
an androgen (a male sex hormone) in 
combination with a synthetic progestin 
(another hormone) can reduce sperm 
count without impairing a man’s sex drive. 
The Council tested this approach in early 
clinical studies, which showed promising 
results by inhibiting sperm production 
using four mENT implants in healthy 
men. The next step will be a randomized 
study to evaluate the safety and efficacy 
of mENT, either alone or in conjunc-
tion with the injectable progestin known 
as DMPA (Depo-Provera®), to determine 
whether the combination of mENT and a 
MALE 
CONTRACEPTION 
IN DISCOvERY
Researchers at the Population 
Council are developing a one-year 
hormonal contraceptive implant 
for men containing the novel 
androgen MENT®. 
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occurring algae protein shown to be safe 
and highly effective against HIv in the lab 
and against HSv-2 and HPv in preclinical 
studies. A griffithsin gel is being tested to 
help develop a sustained-release vaginal 
ring and a nanofiber delivery system (a 
film-like formulation) to provide protection 
at the time of sex. The first human studies 
of griffithsin vaginal gel are expected to 
begin in 2016.
THE IMPACT  If proven effective, these 
MPTs could contribute substantially to 
global health. mZC-based products could 
increase protection against HIv and HSv-2 
at lower doses, which in turn could im-
prove product safety, decrease chances 
of drug resistance, and reduce costs. 
Non-ARv-based mPT products (e.g., those 
containing ZC or griffithsin) could help to 
reduce the emergence of drug-resistant 
HIv types, eliminate the need for HIv 
screening prior to use, and potentially 
be provided over-the-counter. Council 
researchers are working with academic, 
nonprofit, and industry experts to ad-
vance promising candidates through the 
pipeline and to identify strategies for 
introduction and scale-up to ensure that 
mPTs, once available, are accessible to 
those most in need.
COLLABORATORS  Duke University; 
Fraunhofer Center for molecular Biotechnology; 
Promed Pharma; Tulane National Primate 
Research Center; University of Alabama at 
Birmingham; University of Washington
DONORS  U.S. National Institutes of Health 
National Institute of Allergy and Infectious 
Diseases; U.S. President’s Emergency Plan for 
AIDS Relief (PEPFAR); United States Agency for 
International Development (USAID); Sweden 
ministry for Foreign Affairs
THE PROBLEM  male and female 
condoms are currently the only avail-
able products designed to provide con-
current protection against pregnancy 
and sexually transmitted infections 
(STIs), including HIv. Condoms are ef-
fective when used correctly, but there 
are many barriers to use and they are 
not practical for women and couples 
who want to have children. New prod-
ucts are needed to address the needs 
of women and men at risk for STIs, HIv, 
and unintended pregnancy. 
THE PROGRESS  The Population 
Council has long-acting vaginal rings 
and on-demand multipurpose preven-
tion technologies (MPTs) in varying stag-
es of development. Several candidates 
contain a combination of MIV-150 (m), 
an antiretroviral (ARV) drug that prevents 
HIv from infecting target cells; zinc acetate 
(Z), an antiviral agent with activity against 
HIv and genital herpes simplex virus 
(HSv-2); and carrageenan (C), a seaweed-
derived compound active against human 
papillomavirus (HPv). The MZC vaginal 
ring is designed to prevent HIV and other 
STIs for 90 days; the MZCL ring offers 
these same potential benefits and adds 
the contraceptive levonorgestrel (L) to pre-
vent pregnancy. The Council has produced 
and tested prototype rings in preclinical 
and animal studies with promising results 
and recently completed a Phase I clinical 
safety trial of an MZC vaginal gel. A non-
ARV ZC gel has also been found to be safe 
and active against HIv, HPv, and HSv-2 in 
preclinical studies. Products are also be-
ing developed with griffithsin, a naturally 
The Population Council is 
developing multipurpose 
prevention technologies to 
protect against HIV and other 
sexually transmitted infections, 
and in some cases also provide 
contraception, with a single 
product. 
MULTIPURPOSE 
PREvENTION 
TECHNOLOGIES 
IN EARLY-STAGE 
DEvELOPmENT
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to be highly effective in preventing ovula-
tion. The NES/EE ring is inserted by the 
woman, left in place for 21 days, and re-
moved for 7 days. One ring can be used for 
up to 13 cycles (one year), and fertility re-
turns after discontinuing use. The Council 
is preparing to submit a New Drug Applica-
tion to the US Food and Drug Administra-
tion and will seek to introduce the one-year 
NES/EE ring in various settings, including 
in low- and middle-income countries.
THE IMPACT  The PVR is currently 
available to women in Bolivia, Chile, Co-
lombia, Dominican Republic, Ecuador, 
Guatemala, Honduras, and Peru, and the 
market is now expanding to include regula-
tory applications in Brazil and mexico. The 
Council is also working toward product 
introduction in India, Kenya, Nigeria, and 
Senegal, with the goal of expanding to 
other countries. The Council’s one-year 
NES/EE ring, if approved by the FDA, 
would be a unique long-acting reversible 
contraceptive that is effective for 13  
cycles, is under the woman’s control, 
and does not require insertion or remov-
al by a trained healthcare provider.
PARTNERS  Bill & melinda Gates Institute 
for Population and Reproductive Health; 
Grünenthal (formerly Andromaco); International 
Committee for Contraception Research; 
ministries of Health of India, Kenya, Nigeria, 
and Senegal; QPharma; WomenCare Global; 
World Health Organization
DONORS  Barrus Foundation; Bill & melinda 
Gates Foundation; U.S. Agency for International 
Development; U.S. National Institutes of Health 
Eunice Kennedy Shriver National Institute 
of Child Health and Human Development 
Contraceptive Clinical Trials Network
THE PROBLEM  Women in low-
resource settings face unique barriers to 
obtaining effective contraception, includ-
ing limited access to different options 
and a lack of trained health professionals 
to provide services or counseling. In ad-
dition, although exclusive breastfeeding 
may prevent pregnancy for the first six 
months after childbirth, return to fertility 
can occur sooner than anticipated, leav-
ing women at risk for unintended preg-
nancy, unsafe abortion, and poor health 
outcomes. There is an urgent need for 
convenient new contraceptive methods 
that are safe, effective, easy to use, and 
under a woman’s control.
THE PROGRESS  The Council’s 
three-month progesterone vaginal ring 
(PVR) can be used safely by breastfeed-
ing women to help space pregnancies. 
It does not affect lactation and does not 
require insertion by a healthcare provider. 
Each PvR can be used continuously for 
three months, and rings can be used suc-
cessively for up to a year. Fertility returns 
shortly after removal. The ring has been 
available in Latin America since 1998 
under the brand name Progering®. The 
Council is working to introduce the PvR 
in more countries where prolonged lacta-
tion is vital for infant health—and where 
access to highly effective contraceptives 
is limited. 
The one-year ring prevents pregnancy by 
releasing a low dose of ethinyl estradiol 
(EE), an approved, marketed hormonal 
product, and Nestorone® (NES), an investi-
gational progestin that has been shown  
The Population Council has developed two  
innovative contraceptive vaginal rings to  
meet women’s varying family planning needs:  
a three-month ring that contains progesterone 
for use by breastfeeding women, and an 
investigational one-year ring that can prevent 
pregnancy for a full year. 
CONTRACEPTIvE 
vAGINAL RINGS 
IN LATE-STAGE 
DEvELOPmENT
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BRAZIL: Since becoming an ICA Foun-
dation project in 2006, the Center for 
Research in Reproductive Health of 
Campinas (CEMICAMP) and the Univer-
sity of Campinas School of medicine’s 
Department of Obstetrics and Gynecol-
ogy (UNICAmP) has provided an average 
of 271 women per month with free LNG 
IUS insertions at more than 20 sites 
throughout Brazil. It is the Foundation’s 
largest project, having received nearly 
21% of all LNG IUS donations made in 
the past decade (over 14,000 devices) 
and trained nearly 100 health profes-
sionals across Brazil on counseling and 
insertion/removal techniques. The proj-
ect is led by Prof. Dr. Luis Bahamondes, 
an eminent OB/GYN based in Campinas. 
NIGERIA: With 35 sites across Nigeria, 
Rotary International has received 7,500 
LNG IUS donations since becoming an ICA 
Foundation project in 2007. Local partners 
have developed and implemented health 
provider education and community 
outreach activities involving men and re-
ligious leaders in family planning promo-
tion, and women served by project sites 
report very high acceptance of the LNG 
IUS. The project is led by Robert Zinser, 
Chief Executive Officer of the Rotarian 
Action Group for Population and Develop-
ment and a long-standing champion for 
maternal health and family planning.
DONORS  Bayer HealthCare Pharmaceuticals, 
Population Council
THE PROBLEM   The levonorgesterel 
intrauterine system (LNG IUS) provides 
up to five years of safe, effective, and 
continuous contraception. Developed 
by the Population Council and Finland-
based Bayer OY, the LNG IUS is distrib-
uted by Bayer HealthCare Pharmaceu-
ticals in the private market under the 
trade name Mirena® in more than  
120 countries. In low-resource settings, 
the LNG IUS is often inaccessible due  
to financial barriers and supply chain 
challenges. 
THE PROGRESS  The ICA  
Foundation was established in 2003  
to help overcome these obstacles  
by making the LNG IUS available at  
no cost in resource-poor settings.  
To date, the Foundation has provided 
over 67,000 LNG IUS and training ma-
terials to projects in 28 low- and middle-
income countries. To become a project 
of the Foundation, eligible organizations 
must submit an application describing 
their plans for integrating the LNG IUS 
into their reproductive health service  
delivery activities. This local responsibil-
ity ensures that the donated LNG IUS 
are distributed in a culturally-appropri-
ate and acceptable manner.
THE IMPACT  Two of the ICA Foun-
dation’s most successful projects are 
highlighted here to illustrate the impact 
of this important work. 
The International Contraceptive 
Access (ICA) Foundation, a public–
private partnership between the 
Population Council and Bayer OY, is 
helping expand access to long-acting 
reversible contraception in low-
resource settings.
DELIvERING ON A PROmISE: 
THE ICA FOUNDATION
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Tell us about the work you do.
I lead the preclinical virology group in 
the microbicides laboratory at CBR. We 
conduct research to identify compounds 
that might be active against HIV and other 
sexually transmitted pathogens such as 
genital herpes simplex virus (HSv-2) and 
human papillomavirus (HPv). After one or 
more compounds has been formulated 
as a product candidate (for example, as 
you read about on page 8) and before 
any human testing is done, we conduct 
rigorous studies on these microbicide and 
multipurpose prevention technology (MPT) 
candidates to ensure they are safe and 
effective. These preclinical studies are nec-
essary in order to identify the most promis-
ing microbicide and MPT candidates to be 
further developed and tested in people.
Why did you choose to do this work 
at the Council?
The Population Council has a rich history 
of improving the lives and expectations 
of millions of people. Our HIv prevention 
program follows the same philosophy of 
empowering the world’s most vulnerable 
by working to make user-controlled 
microbicides and mPTs a reality.
What led you to enter the field of 
biomedical research?
my passion for virology started 20 years 
ago when I began studying microbiology. 
This was back in the 1990s, when people 
A CONvERSATION WITH
JOSÉ FERNÁNDEZ ROmERO
SCIENTIST AT THE POPULATION COUNCIL’S  
CENTER FOR BIOmEDICAL RESEARCH (CBR)
began paying more attention to the global 
impact of HIv and AIDS. After I received 
my bachelors degree in microbiology 
at the University of Havana, I stayed to 
teach virology and genetic engineering 
while conducting research on indigenous 
plants and their potential for antiviral ac-
tivity. Soon after I arrived in the US from 
Cuba, the Council introduced me to the 
new idea of HIv prevention through micro-
bicides, and I decided to use my exper-
tise in virology to serve the microbicide 
research community. Today my goal is to 
help develop potential MPTs that protect 
women and men not only from HIv but 
also other sexually transmitted infections 
(STIs) and unintended pregnancy.  
What has been most rewarding  
for you in your career?
I have enjoyed helping build a team with 
the unique expertise to test potential 
products against three major, non-
curable viral STIs. I am lucky to work with 
colleagues who understand the impor-
tance of teamwork and are passionate 
about the work we do. I also teach biol-
ogy and microbiology at Hostos Commu-
nity College in the Bronx—a gratifying ex-
perience for me, especially when some of 
my students, many of whom are minori-
ties, decide to pursue a career in biology. 
I hope that by teaching at Hostos, I can 
make a modest contribution to raise the 
profile of minorities in the sciences.
PROFILE
BARBARA EBERT
WHY I GIvE TO THE  
POPULATION COUNCILI give to the Population Council 
because of the long association my late 
husband, Dr. Robert Ebert, had with 
the organization—30 years as a board 
member, 10 years as chair. He considered 
the Population Council one of the most 
important and effective organizations he 
had the privilege of serving.
Bob spent his career in academic 
medicine―as bench scientist, clinician, 
and medical school dean. He worked 
on new drugs to treat tuberculosis and 
was continually challenged to translate 
his research to the bedside as quickly 
as possible. He saw how new drugs 
improved people’s lives. He cared deeply 
about public health issues, including 
efficient and cost-effective delivery of 
medical care to needy populations, 
prevention of communicable diseases, 
and family planning. Becoming a trustee 
of the Population Council extended his 
interest in public health to the global 
level. He became even more committed to 
developing new products and initiatives to 
improve the reproductive health of women 
in developing nations.
It was my privilege and good fortune to 
accompany him on some board meetings 
in Africa. One took us to Senegal and 
mali, where we visited clinics for and 
managed by women. These women 
stressed the importance of good health, 
prenatal care, and family planning. When 
we arrived at one clinic, the clients, 
having been told that Population 
Council Trustees were coming to visit, 
were waiting for us all dressed up. They 
passed their babies to us to hold and 
coo over (in fractured French for most 
of us). They used theater to illustrate 
the important health issues they faced; 
we saw two skits in which women 
impressed upon their husbands the 
importance of family planning. They 
played these parts with a good deal 
of humor—including an irate mother 
who browbeat her son for getting his 
wife pregnant again—and were very 
effective in putting their point across. 
While I make modest gifts to other  
family planning organizations, I am 
particularly impressed with the broad 
scope of the Council’s influence 
throughout the world. Family planning 
is obviously one, but the work of the 
Center for Biomedical Research in 
developing safe, innovative, and afford-
able contraceptives has made a huge 
impact in this area. Addressing other  
issues such as HIv prevention, educa-
tion and safe spaces for girls, and pov-
erty alleviation makes the Population 
Council stand out as a leader.
COUNCIL DONOR
1716
WITH YOUR HELP, WE CAN 
CONTINUE TO PROVIDE 
PEOPLE WITH NEW PRODUCTS 
TO SAFEGUARD THEIR 
REPRODUCTIVE HEALTH AND 
WELLBEING.
Support the  
Population Council: 
popcouncil.org/supporting
Sign up for the Council’s  
e-mail list: 
popcouncil.org  
(Click “Subscribe” on the homepage) 
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